Back to School: How biopharma can reboot drug development. Access exclusive analysis here

SkyePharma: Healing a technology

While some biotechnologies charge ahead at the forefront of their fields, others limp along at the rear. While many limpers have been eclipsed by more effective technologies, others have value and simply need help to realize their potential.

SkyePharma plc acquired a limper, Geomatrix

Read the full 439 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers